日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study

二甲富马酸酯在常规医疗实践中治疗多发性硬化症患者中的长期安全性和有效性：ESTEEM 研究的最终分析

期刊:Neurology and Therapy
影响因子:4.8
doi:10.1007/s40120-024-00680-z
Pandey, Krupa Shah; Giles, Kathryn; Balashov, Konstantin; Macdonell, Richard; Windsheimer, Jörg; Martinez, Mikel; Božin, Ivan; Raynaud, Stephanie; Scaramozza, Matthew; Mokliatchouk, Oksana; Sun, Zhaonan; Belviso, Nicholas; Sato, Yayoi; Lin, Xiaochen; Okai, Annette
神经科学
多发性硬化症
发表日期：2025
文献求助 收藏

Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients

二甲富马酸酯在多发性硬化症患者中的真实世界安全性和有效性：ESTEEM 4期和PROCLAIM 3期研究的结果，重点关注老年患者

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-024-03047-w
Mao-Draayer, Yang; Bar-Or, Amit; Balashov, Konstantin; Foley, John; Smoot, Kyle; Longbrake, Erin E; Robertson, Derrick; Mendoza, Jason P; Lewin, James B; Everage, Nicholas; Božin, Ivan; Lyons, Jennifer; Mokliatchouk, Oksana; Bame, Eris; Giuliani, Fabrizio
神经科学
多发性硬化症
发表日期：2025
文献求助 收藏

Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial

富马酸二甲酯与干扰素β-1a治疗儿童期发病多发性硬化症患者的疗效比较：CONNECT随机临床试验

期刊:Jama Network Open
影响因子:9.7
doi:10.1001/jamanetworkopen.2022.30439
Vermersch, Patrick; Scaramozza, Matthew; Levin, Seth; Alroughani, Raed; Deiva, Kumaran; Pozzilli, Carlo; Lyons, Jennifer; Mokliatchouk, Oksana; Pultz, Joe; N'Dure, Fatou; Liu, Shifang; Badwan, Runda; Branco, Filipe; Hood-Humphrey, Valencia; Franchimont, Nathalie; Hanna, Jerome; Maghzi, Amir-Hadi
神经科学
多发性硬化症
发表日期：2022
文献求助 收藏

Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry

前瞻性国际登记研究中，暴露于富马酸二甲酯后妊娠结局的中期分析

期刊:Neurology-Neuroimmunology & Neuroinflammation
影响因子:7.5
doi:10.1212/NXI.0000000000001114
Hellwig, Kerstin; Rog, David; McGuigan, Christopher; Houtchens, Maria K; Bruen, Denise R; Mokliatchouk, Oksana; Branco, Filipe; Peng, Xiaomei; Everage, Nicholas J
发表日期：2022
文献求助 收藏

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results

二甲基富马酸酯治疗复发缓解型多发性硬化症患者长达13年的长期安全性和有效性：ENDORSE研究最终结果

期刊:Multiple Sclerosis Journal
影响因子:5
doi:10.1177/13524585211037909
Gold, Ralf; Arnold, Douglas L; Bar-Or, Amit; Fox, Robert J; Kappos, Ludwig; Mokliatchouk, Oksana; Jiang, Xiaotong; Lyons, Jennifer; Kapadia, Shivani; Miller, Catherine
神经科学
多发性硬化症
发表日期：2022
文献求助 收藏

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies

富马酸二甲酯对复发缓解型多发性硬化症脑萎缩的影响：DEFINE 和 CONFIRM 3 期研究的汇总分析

期刊:Frontiers in Neurology
影响因子:2.8
doi:10.3389/fneur.2022.809273
Nakamura, Kunio; Mokliatchouk, Oksana; Arnold, Douglas L; Yousry, Tarek A; Kappos, Ludwig; Richert, Nancy; Ayling-Rouse, Katherine; Miller, Catherine; Fisher, Elizabeth
神经科学
多发性硬化症
发表日期：2022
文献求助 收藏

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

一项 I 期研究旨在确定双重 VEGFR 和 FGFR 抑制剂 brivanib 在晚期或转移性实体瘤患者中的安全性、药代动力学和药效学。

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdq599
Jonker, D J; Rosen, L S; Sawyer, M B; de Braud, F; Wilding, G; Sweeney, C J; Jayson, G C; McArthur, G A; Rustin, G; Goss, G; Kantor, J; Velasquez, L; Syed, S; Mokliatchouk, O; Feltquate, D M; Kollia, G; Nuyten, D S A; Galbraith, S
VEGF
EGF
EGFR
发表日期：2011
文献求助 收藏